Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdul L. Shakerdi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Inborn Errors of Amino Acid Metabolism Revisited: Clinical Implications and Insights into Current Therapies

    by Abdul L. Shakerdi, Darragh Nerney, Eleanor J. Molloy, Ina Knerr

    Background/Objectives: Inborn errors of amino acid metabolism (IEAAMs) are inherited disorders caused by defects in amino acid catabolism, biosynthesis, or transport. In this review, we aimed to synthesise recent evidence on the clinical manifestations and current and future therapeutic strategies for major IEAAMs. Methods: A narrative review was undertaken on studies published up to November 2025. No fixed start date was set. Instead, earlier studies were included if historically significant or frequently cited in contemporary guidelines, and emphasis was placed on recent developments over the last 5–10 years. Evidence was identified through structured searches of PubMed, clinical trial registries, and public communications on selected IEAAMs, which were synthesised in textual and tabular form. Results: Management across IEAAMs involves the restriction of amino acids or natural proteins, disease-specific dietary formulations, micronutrient optimisation, cofactor or enzyme replacement, and pharmacological chaperones. This is supported by structured monitoring and emergency regimens to prevent catabolic crises. Organ transplantation remains crucial for select indications, such as liver transplantation in hereditary tyrosinaemia with liver disease. Novel approaches include substrate reduction, the pharmacological targeting of upstream pathways, viral vector gene transfer, and liver-directed mRNA therapy. Several of these novel approaches have entered clinical trials, but many remain in the preclinical stage. Conclusions: Despite advances in the treatment of IEAAMs, many patients still experience significant morbidity. Future focus should be on further refining emerging molecular and gene-based treatments and optimising neuroprotective and metabolic targets. The equitable implementation of personalised, life-spanning treatments within multidisciplinary rare disease services will be essential.


  • Open Access

    Inborn Errors of Amino Acid Metabolism Revisited: Clinical Implications and Insights into Current Therapies

    by Abdul L. Shakerdi, Darragh Nerney, Eleanor J. Molloy, Ina Knerr

    Inborn errors of amino acid metabolism (IEAAMs) are a heterogeneous group of genetic disorders caused by defects in enzymes, cofactors, or transporters of amino acid catabolism, biosynthesis, or transport. These defects result in toxic metabolite accumulation and/or deficiency of essential metabolites. This review aims to provide an updated overview of diagnosis, clinical implications, management, and evolving therapeutic approaches across major IEAAMs. A narrative review of recent literature was undertaken, focusing on established and novel therapeutic strategies for key IEAAMs, including phenylketonuria, alkaptonuria, tyrosinemia, homocystinuria, and maple syrup urine disease. Key management strategies include amino acid-restricted diets/restriction of natural protein with restriction of dietary precursors, dietary supplementations, including disease-specific amino acid supplements, medications to reduce formation of offending metabolites, pharmacotherapies, enzyme/cofactor replacement or pharmacological chaperones, enhancing residual enzyme activity and promoting alternative path-ways/accessory pathways. Emergency therapy is essential in severe types and focuses on promoting anabolism, limiting catabolism, reducing formation, and enhancing clearance of toxic metabolites. Other treatment options include organ transplantation, and new emerging modalities, such as mRNA therapies and gene therapies/in vivo gene editing offer potential for definitive interventions. Despite advancements in therapy and close monitoring, many IEAAMs remain associated with significant comorbidities. Future research is essential to optimise current treatment standards, particularly neuroprotective and metabolic regulatory features. While an in-depth discussion of innovative person-alised therapies is beyond the scope of this article, we believe that collective experiences will thrust future research in this field and expand access to innovative personalised therapies.


  • Open Access

    Crosstalk Between Inflammasome Signalling and Epithelial-Mesenchymal Transition in Cancer and Benign Disease: Mechanistic Insights, Context-Dependence, and Therapeutic Opportunities

    by Abdul L. Shakerdi, Emma Finnegan, Yin-Yin Sheng, Karlo Vidovic, Jessica M. Logan, Mark P. Ward, Sharon A. O’toole, Cara Martin, Stavros Selemidis, Doug Brooks, et al.

    Epithelial-mesenchymal transition (EMT) and inflammasome signalling are intercon-nected processes which underpin tumour progression, metastasis, and therapeutic re-sistance. Inflammasomes such as NLRP3 encourage pro-inflammatory states (IL-1β, IL-18, NF-κB) and the activation of signalling pathways like TGF-β that promote mes-enchymal traits crucial for EMT. EMT transcriptional programmes can then in turn modulate the inflammasome via NF-κB/TGF-β signalling, creating self-perpetuating mechanisms of cellular plasticity and dysregulated therapeutic response. We have re-viewed the mechanistic evidence for EMT–inflammasome crosstalk in cancer and discussed the potential therapeutic implications. The function of the EMT-inflammasome axis is clearly context-dependent, with the cancer type, stage, and the complexity of the tumour microenvironment heavily contributing. The crosstalk between EMT and the inflammasome is an overlooked mechanism of tumour evolution, and targeting inflammasomes like NLRP3, or their downstream signalling pathways, offers a promising therapeutic avenue, with the objective of inhibiting metastasis and overcoming drug resistance.


  • Open Access

    Crosstalk Between Inflammasome Signalling and Epithelial-Mesenchymal Transition in Cancer: Mechanistic Insights, Context-Dependence, and Therapeutic Opportunities

    by Abdul L. Shakerdi, Emma Finnegan, Yin-Yin Sheng, Karlo Vidovic, Jessica M Logan, Mark P. Ward, Sharon A. O'Toole, Cara M Martin, Stavros Selemidis, Doug Brooks, et al.

    Epithelial-mesenchymal transition (EMT) and inflammasome signaling are interconnected processes which underpin tumour progression, metastasis, and therapeutic resistance. Inflammasomes such as NLRP3 encourage pro-inflammatory states (IL-1β, IL-18, NF-κB) and the activation of signalling pathways like TGF-β that promote mesenchymal traits crucial for EMT. EMT transcriptional programs can then in turn modulate the inflammasome via NF-κB/TGF-β signaling, creating self-perpetuating mechanisms of cellular plasticity and dysregulated therapeutic response. We have reviewed the mechanistic evidence for EMT–inflammasome crosstalk in cancer and discussed the potential therapeutic implications. The function of the ENT-inflammasome axis is clearly context-dependent, with the cancer type, stage, and the complexity of the tumour microenvironment heavily contributing. The between EMT and the inflammasome is an overlooked mechanism of tumour evolution and targeting inflammasomes like NLRP3, or their downstream signalling pathways offer a promising therapeutic avenue, with the therapeutic objective of reducing metastasis and overcoming drug resistance.


  • Open Access

    MicroRNA-mediated regulation of autophagy in lung cancer: role in tumourigenesis and chemotherapy resistance

    by Yin Yin Sheng, Abdul L. Shakerdi, Graham P. Pidgeon

    Autophagy is an evolutionarily conserved catabolic process that enables cells to degrade and recycle long-lived proteins and damaged organelles, playing an important role in cellular homeostasis and survival under stress. In lung cancer, autophagy has emerged as a key modulator of tumour cell survival and is a significant factor influencing chemotherapy efficacy. However, the contribution of autophagy to chemoresistance remains complex and incompletely understood. Recent studies identify microRNA (miRNAs), a class of small non-coding RNAs, as critical regulators of autophagy, capable of modulating autophagy-related genes and signalling pathways. Through this regulatory capacity, miRNAs can alter autophagic activity in lung cancer cells, thereby influencing both chemosensitivity and the development of chemoresistance. This review summarises current advances in the understanding of the miRNA-mediated regulation of autophagy in the context of lung cancer, with particular emphasis on its impact on chemotherapy response. Mechanistic insights into how miRNAs govern specific stages of the autophagic process are examined, and the potential for therapeutic intervention targeting the miRNA–autophagy axis to mitigate chemoresistance in lung cancer is discussed.


  • Open Access

    The Multifaceted Role of Autophagy in Nasopharyngeal Carcinoma: Translational Perspectives on Pathogenesis, Biomarkers, Treatment Resistance, and Emerging Therapies

    by Abdul L. Shakerdi, Emma Finnegan, Yin-Yin Sheng, Graham P. Pidgeon

    Background: Nasopharyngeal carcinoma (NPC) is an epithelial malignancy arising from the nasopharyngeal mucosa. Despite treatment advances such as the use of intensity-modulated radiotherapy and immune checkpoint inhibitors, resistance remains a significant clinical challenge. Many tumours are also diagnosed at an advanced stage associated with poor prognosis. Objective: This review aims to explore the biological roles of autophagy in NPC, primarily highlighting its involvement in disease pathogenesis and treatment resistance. Methods: We performed a review of the recent literature examining the role of autophagy-related pathways in NPC pathogenesis, biomarker discovery, and therapeutic targeting. Results: Autophagy plays a dual role in NPC as it contributes to both tumour suppression and progression. It is involved in tumour initiation, metastasis, immune modulation, and treatment resistance. Autophagy-related genes such as SQSTM1, Beclin-1, and AURKA may serve as prognostic and therapeutic biomarkers. Various strategies are being investigated for their role to modulate autophagy using pharmacologic inhibitors, RNA interventions, and natural compounds. Conclusions: Further research into autophagy’s context-dependent roles in NPC may inform the development of personalised therapies and allow progress in translational and precision oncology.


  • Open Access

    The Multifaceted Role of Autophagy in Nasopharyngeal Carcinoma: Translational Perspectives on Pathogenesis, Biomarkers, Treatment Resistance, and Emerging Therapies

    by Abdul L. Shakerdi, Emma Finnegan, Yinyin Sheng, Graham P. Pidgeon

    Background: Nasopharyngeal carcinoma (NPC) is an epithelial malignancy arising from the nasopharyngeal mucosa. Despite treatment advances such as the use of intensity-modulated radiotherapy and immune checkpoint inhibitors, resistance remains a significant clinical challenge. Many tumours are also diagnosed at an advanced stage associated with poor prognosis. Objective: This review aims to explore the biological roles of autophagy in NPC, primarily highlighting its involvement in disease pathogenesis and treatment resistance. Methods: We performed a review of recent literature examining the role of autophagy-related pathways in NPC pathogenesis, biomarker discovery, and therapeutic targeting. Results: Autophagy plays a dual role in NPC as it contributes to both tumour suppression and progression. It is involved in tumour initiation, metastasis, immune modulation, and treatment resistance. Autophagy-related genes such as SQSTM1, Beclin-1, and AURKA may serve as prognostic and therapeutic biomarkers. Various strategies are being investigated for their role to modulate autophagy using pharmacologic inhibitors, RNA interventions, and natural compounds. Conclusions: Further research into autophagy’s context-dependent roles in NPC may inform the development of personalised therapies and allow progress in translational and precision oncology.


  • Open Access

    SMARCB1 Deficiency as a Driver of the Hallmarks of Cancer in Rhabdoid Tumours: Novel Insights into Dysregulated Energy Metabolism, Emerging Targets, and Ongoing Clinical Trials

    by Abdul L. Shakerdi, Graham P. Pidgeon

    Background: Rhabdoid tumours (RTs) are aggressive neoplasms most often characterised by biallelic loss of the SMARCB1 gene, encoding a core subunit of the SWI/SNF chromatin-remodelling complex. Despite their relative genetic stability, RTs exhibit a highly malignant phenotype and poor prognosis. Methods: This review explores the mechanisms underlying SMARCB1 aberrations, their role in driving hallmarks of cancer, and emerging therapeutic strategies for RTs. Ongoing clinical trials listed on ClinicalTrials were reviewed to evaluate the translational potential of targeted therapies in SMARCB1-deficient rhabdoid tumours. Results: Loss of SMARCB1 drives multiple cancer hallmarks by disrupting key regulatory pathways. It promotes unchecked cell proliferation through alterations in p16INK4a and Myc signalling. SMARCB1-deficient tumours possess immune-evading capabilities via PD-L1 overexpression and immune checkpoint activation. SMARCB1 deficiency also alters cellular energetics. The nucleotide biosynthesis pathway has been demonstrated to be upregulated in RT organoids, as shown by increased levels of pathway metabolites. Enzymes of the mevalonate pathway such as HMG-CoA reductase and mevalonate kinase are also dysregulated. Targeting glutathione metabolism with eprenetapopt may induce oxidative stress and apoptosis. Widespread epigenetic aberrations, including increased EZH2 activity, are being targeted with inhibitors such as tazemetostat. Conclusions: SMARCB1 loss is a central driver of cancer hallmarks in RTs, enabling proliferation, immune evasion, metabolic reprogramming, and epigenetic dysregulation. Future horizons in RT treatment include immunotherapies, epigenetic modifiers, and gene therapies. The synergy and optimal timing of targeted therapy with conventional treatment requires further characterisation for clinical translation.